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Summary
Background Severe malaria is a major cause of childhood death and often the main reason for paediatric hospital 
admission in sub-Saharan Africa. Quinine is still the established treatment of choice, although evidence from Asia 
suggests that artesunate is associated with a lower mortality. We compared parenteral treatment with either artesunate 
or quinine in African children with severe malaria. 
Methods This open-label, randomised trial was undertaken in 11 centres in nine African countries. Children (<15 years) 
with severe falciparum malaria were randomly assigned to parenteral artesunate or parenteral quinine. Randomisation 
was in blocks of 20, with study numbers corresponding to treatment allocations kept inside opaque sealed paper 
envelopes. The trial was open label at each site, and none of the investigators or trialists, apart from for the trial 
statistician, had access to the summaries of treatment allocations. The primary outcome measure was in-hospital 
mortality, analysed by intention to treat. This trial is registered, number ISRCTN50258054.
Findings 5425 children were enrolled; 2712 were assigned to artesunate and 2713 to quinine. All patients were analysed 
for the primary outcome. 230 (8·5%) patients assigned to artesunate treatment died compared with 297 (10·9%) 
assigned to quinine treatment (odds ratio [OR] stratiﬁ ed for study site 0·75, 95% CI 0·63–0·90; relative reduction 
22·5%, 95% CI 8·1–36·9; p=0·0022). Incidence of neurological sequelae did not diﬀ er signiﬁ cantly between groups, 
but the development of coma (65/1832 [3·5%] with artesunate vs 91/1768 [5·1%] with quinine; OR 0·69 95% CI 
0·49–0·95; p=0·0231), convulsions (224/2712 [8·3%] vs 273/2713 [10·1%]; OR 0·80, 0·66–0·97; p=0·0199), and 
deterioration of the coma score (166/2712 [6·1%] vs 208/2713 [7·7%]; OR 0·78, 0·64–0·97; p=0·0245) were all 
signiﬁ cantly less frequent in artesunate recipients than in quinine recipients. Post-treatment hypoglycaemia was also 
less frequent in patients assigned to artesunate than in those assigned to quinine (48/2712 [1·8%] vs 75/2713 [2·8%]; 
OR 0·63, 0·43–0·91; p=0·0134). Artesunate was well tolerated, with no serious drug-related adverse eﬀ ects.
Interpretation Artesunate substantially reduces mortality in African children with severe malaria. These data, together 
with a meta-analysis of all trials comparing artesunate and quinine, strongly suggest that parenteral artesunate should 
replace quinine as the treatment of choice for severe falciparum malaria worldwide.
Funding The Wellcome Trust.
Introduction
Falciparum malaria is a major contributor to child 
mortality in Africa and one of the main causes of 
paediatric hospital admission across sub-Saharan Africa. 
Many deaths occur in or near the home, but for children 
who are admitted to hospital with severe malaria and 
receive parenteral antimalarial treatment, about one in 
six will die.1,2 From the time of its introduction to European 
medicine in the 1630s until the deployment of parenteral 
chloroquine in the 1950s, quinine was the mainstay of 
severe malaria treatment. Resistance to chloroquine 
emerged in southeast Asia and then spread to Africa at 
the end of the 1970s. Quinine then resumed its primary 
role in the treatment of severe malaria. Parenteral quinine 
has a narrow therapeutic ratio.1–3 Intravenous quinine 
administration needs a constant rate infusion with dosing 
three times a day. Intramuscular administration is 
painful, and can cause sterile abscesses and predispose to 
lethal tetanus.4 Although blindness and deafness may 
follow self poisoning, these side-eﬀ ects are rare in severe 
malaria; however, quinine-induced hyperinsulinaemic 
hypoglycaemia is a particular problem in patient manage-
ment, especially in pregnant women.1,2,5
The primacy of quinine in the treatment of severe 
malaria has been challenged by the introduction of 
artemisinin derivatives. The ﬁ rst comparative clinical trials 
were done with intramuscular artemether—a lipophilic 
derivative of dihydroartemisinin. Artemether proved safer 
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and easier to use than quinine, but did not improve overall 
survival in an individual patient data meta-analysis6 of 
1919 randomised patients. In a prospectively deﬁ ned 
subgroup analysis, artemether reduced mortality 
signiﬁ cantly in southeast Asian adults, but not in African 
children. A large multicentre randomised trial (South East 
Asian Quinine Artesunate Malaria Trial [SEAQUAMAT]),7 
which compared intra venous artesunate with quinine in 
Asian patients (mainly adults) with severe malaria was 
then undertaken. It was stopped after enrolment of 
1461 patients because of a substantial survival beneﬁ t in 
favour of artesunate. In a meta-analysis of the 
SEAQUAMAT study and earlier, smaller randomised 
trials,7 artesunate reduced the mortality of severe malaria 
in Asian patients from 23·1% to 14·2%, a relative reduction 
of 38·6%. The treatment was also highly cost eﬀ ective.8 In 
2006, WHO changed its guidelines to recommend 
artesunate for severe malaria in adults.9
The treatment eﬀ ect in the SEAQUAMAT trial was 
similar in adults and the 202 children enrolled, but 
perceived diﬀ erences in the natural history and drug 
susceptibility of severe falciparum malaria in African 
children compared with Asian patients left uncertainty 
about the optimum treatment for this important patient 
group. Expert opinion regarded parenteral quinine as a 
satisfactory treatment, and research priorities focused on 
improving other aspects of the care of the sick child. 
Nowadays quinine remains by far the most widely used 
treatment of severe malaria in Africa. We undertook a 
large multicentre randomised trial (African Quinine 
Artesunate Malaria Trial [AQUAMAT]) that compared 
parenteral treatment with either artesunate or quinine in 
African children with severe malaria.
Methods
Study design
This was a multicentre, open-label trial in children 
admitted to hospital with severe malaria, undertaken 
between Oct 3, 2005, and July 14, 2010. 11 centres in nine 
countries (Mozambique, The Gambia, Ghana, Kenya, 
Tanzania, Nigeria, Uganda, Rwanda, and Democratic 
Republic of the Congo) in Africa partici pated. The study 
was coordinated by the Mahidol-Oxford Tropical Medicine 
Research Unit in Bangkok, Thailand, which provided 
logistic support and data management. All clinicians were 
familiarised with the severe malaria criteria for enrolment 
(panel 1). Most children were managed on general paedi-
atric wards. Children younger than 15 years were included 
if they had a positive rapid diagnostic test for Plasmodium 
falciparum lac tate dehydrogenase (Optimal, Diamed, 
Cressier, Switzer land) and, in the admitting physician’s 
clinical opinion, they had severe malaria, and they or their 
attendant relative or guardian gave fully informed written 
consent. Patients were not included if there was a 
convincing history of full treatment with parenteral quin-
ine or an artemisinin derivative for more than 24 h before 
admission. Age criteria varied slightly between sites at the 
request of the respective ethics review boards (webappendix 
p 13). In Mozambique, adults were also studied but were 
analysed separately and will be reported elsewhere.
The trial protocol was reviewed and approved by each 
site’s ethics review board, and by the Oxford Tropical 
(Prof A K Tshefu MD, 
M A Onyamboko MB); Mahidol 
Oxford Tropical Medicine 
Research Unit (MORU), Faculty 
of Tropical Medicine, Mahidol 
University, Bangkok, Thailand 
(A M Dondorp MD, 
C I Fanello PhD, 
I C E Hendriksen MD, 
T Sakulthaew BNS, 
W Pan Ngum PhD, K Silamut PhD, 
K Stepniewska PhD, 
C J Woodrow MRCP, 
Prof N P J Day FRCP, 
Prof N J White FRS); Nuﬃ  eld 
Department of Clinical 
Medicine, University of Oxford, 
Oxford, UK (D Bethell MRCPCH, 
Prof T E Peto FRCP); Menzies 
School of Health Research, 
Casuarina, NT, Australia 
(L von Seidlein PhD); Oxford 
University Clinical Research 
Unit, Ho Chi Minh City, Vietnam 
(B Wills FRCPCH); and KEMRI—
CDC Kisumu, Kisumu Kenya 
(M Oneko MD)
Panel 1: Modiﬁ ed criteria for severe falciparum malaria
At least one of:
• Plasma base excess less than –3·3 mmol/L
• Glasgow coma scale less than 11 of 15, or Blantyre coma 
scale less than 3 of 5 in preverbal children
• Haemoglobin less than 50 g/L and parasitaemia greater 
than 100 000 parasites per μL
• Blood urea greater than 10 mmol/L
• Compensated shock (capillary reﬁ ll ≥3 s or temperature 
gradient on legs, but no hypotension)
• Decompensated shock; systolic blood pressure less than 
70 mm Hg and cool peripheries
• Asexual parasitaemia more than 10%
• Visible jaundice and more than 100 000 parasites per μL
• Plasma glucose less than 3 mmol/L
• Respiratory distress, deﬁ ned as costal indrawing, use of 
accessory muscles, nasal alar ﬂ aring, deep breathing, or 
severe tachypnoea
Figure 1: Trial proﬁ le
*663 in Beira, 442 in Kiliﬁ , 436 in Kumasi, 921 in Muheza, 540 in Korogwe, 502 in Banjul, 450 in Ilorin, 386 in 
Rwanda, 663 in Mbarara, and 422 in Kinshasa. †Two patients also had other criteria.
11 148 assessed for eligibility
5425 enrolled*
2712 randomised to artesunate 2713 randomised to quinine
2712 analysed by intention to treat 2713 analysed by intention to treat
149 excluded from per-protocol analysis
17 blood smear negative†
112 missing slides
6 died before receiving drug
7 missed early treatment dose(s)
7 unknown number of treatment doses
2 withdrawn consent
2563 analysed per protocol 2552 analysed per protocol
161 excluded from per-protocol analysis
25 blood-smear negative
99 missing slides
22 died before receiving drug
4 missed early treatment dose(s)
8 unknown number of treatment doses
3 did not fulﬁl entry criteria
5723 excluded
223 insuﬃcient clinical severity criteria
4910 negative or invalid rapid diagnostic test
180 parenteral antimalarial treatment >24 h
316 refused consent
23 died before enrolment
25 below age or weight criteria
46 other reasons
For more about AQUAMAT see 
http://www.tropmedres.ac/
aquamat
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Research Ethics Committee. Permission to investigate 
HIV status was obtained only from some ethics 
review boards.
Randomisation and masking
Eligible patients were randomly assigned to treatment with 
either intravenous or intramuscular artesunate or quinine. 
Each centre had a policy of using one route of 
administration. Randomisation was done by people 
unrelated to the study and provided to the study sites in 
blocks of 20. Study numbers were kept inside opaque 
sealed paper envelopes. After full informed written consent 
was obtained, the next envelope, which contained a unique 
study box number, was opened by the study physician or 
nurse. Then the corresponding numbered sealed box was 
opened. This box contained the study drug, case record 
form (labelled with the unique study number), and all 
disposables needed for drug administration and blood 
sampling. Treatment was started immediately. All other 
Quinine
(N=2713)
Artesunate
(N=2712)
Female sex 1295 (48%) 1315 (48%)
Age (years) 2·9 (1·7–4·3) 2·8 (1·6–4·2)
Fever before enrolment (days) 3 (2–4) 3 (2–4)
Coma before enrolment (h) 5·0 (2·5–10) 5·0 (2·0–9·5)
Pretreatment with antimalarials 
None 1270 (47%) 1281 (47%)
Ineﬀ ective* 371 (14%) 387 (15%)
Eﬀ ective* 959 (37%) 938 (36%)
Complications on admission
Coma† 945 (35%) 880 (32%)
Convulsions 879 (32%) 811 (30%)
Jaundice 59 (2%) 55 (2%)
Severe anaemia (haemoglobin 
<50 g/L)
692 (29%) 737 (30%)
Shock 339 (12%) 323 (12%)
Decompensated shock 88 (35%) 90 (39%)
Severe acidosis (BE <–8 mmol/L) 975 (43%) 1009 (44%)
Hypoglycaemia (<3 mmol/L) 278 (10%) 277 (10%)
Respiratory distress‡ 428 (16%) 439 (16%)
Severe prostration§ 1668 (61%) 1683 (62%)
Blackwater fever 116 (4%) 121 (4%)
Hyperparasitaemia (>10%) 573 (24%) 584 (25%)
Clinical examination
Weight (kg) 12·6 (4·6) 12·4 (4·8)
Temperature (°C) 38·0 (1·1) 38·0 (1·1)
Blood pressure (mm Hg)
Systolic 95 (16) 95 (16)
Diastolic 56 (14) 56 (14)
Coma depth (total N, median 
[IQR])
Blantyre coma score 1704, 4 (2–5) 1713, 4 (2–5)
Glasgow coma score 1005, 11 (8–15) 999, 11 (8–15)
Comorbidity 
Immune compromised (from 
history)
49 (2%) 45 (2%)
Severe malnutrition 43 (2%) 54 (2%)
(Continues in next column)
Quinine
(N=2713)
Artesunate
(N=2712)
(Continued from previous column)
Suspected pneumonia 226 (8%) 227 (8%)
Conﬁ rmed by radiograph 29 (13%) 29 (13%)
Clinical sepsis 355 (13%) 302 (11%)
Conﬁ rmed by culture 33 (9%) 32 (11%)
Suspected meningitis 166 (6%) 169 (6%)
Conﬁ rmed meningitis 3 (2%) 6 (4%)
Other signiﬁ cant comorbidities 71 (3%) 80 (3%)
Laboratory assessments
Parasitaemia (parasites per μL; 
geometric mean, range)
49 110 
(0–1 858 880)
47 922 
(0–1 494 640)
Sodium (mmol/L) 132 (6·5) 131 (6·5)
Potassium (mmol/L) 4·1 (0·9) 4·1 (0·9)
Chloride (mmol/L) 105 (10) 105 (10)
Blood urea nitrogen (mmol/L) 6·1 (4·9) 6·1 (4·6)
Haemoglobin (g/L) 70 (31) 68 (29)
pH 7·36 (0·14) 7·36 (0·14)
PaCO2 (mm Hg) 28·2 (10·1) 27·9 (9·1)
HCO3 (mmol/L) 16·6 (5·7) 16·6 (5·6)
Plasma BE (mmol/L) –8·6 (7·3) –8·5 (7·3)
Anion gap (mmol/L) 17·2 (5·0) 17·0 (4·9)
Data are number (%), median (IQR), or mean (SD), unless otherwise indicated. 
BE=base excess . PaCO2=partial pressure of carbon dioxide. HCO3=bicarbonate. 
*See webappendix p 12 for classiﬁ cation of categories. †Depth of coma was 
assessed either by Blantyre coma score (for preverbal children, n=3417) or 
Glasgow coma scale (n=2004). ‡Respiratory distress was deﬁ ned as costal 
indrawing, use of accessory muscles, nasal alar ﬂ aring, deep breathing, or severe 
tachypnoea. §Severe prostration was deﬁ ned as inability to breastfeed for children 
younger than 6 months or inability to sit for older children.
Table 1: Baseline characteristics in the two treatment groups
Figure 2: Kaplan-Meier curves comparing survival in African children with severe falciparum malaria treated 
with either parenteral artesunate or quinine
The numbers in parentheses are the deaths during the indicated time. In eight patients the exact time of death 
during the night was missing and was estimated as 2359 h. 
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See Online for webappendix
Correspondence to:
Prof N J White, Faculty of Tropical 
Medicine, Mahidol University, 
420/6 Rajvithi Road, 
Bangkok 10400, Thailand
nickw@tropmedres.ac
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aspects of supportive treatment, based on WHO guidelines, 
were unaﬀ ected by the trial.1,2,9
Although the trial was open label at each site, none of 
the investigators or trialists, apart from for the trial 
statistician (TEP), had access to the summaries of 
treatment allocations. When notes or case record forms 
were reviewed, all study drug details were removed to 
preserve masking. All case reviews and laboratory 
assessments were done blinded to treatment allocation, 
which was not revealed until the database was locked at 
the end of the trial.
Procedures
Artesunate (Guilin Pharmaceutical Factory, Guangxi, 
China) was given in a dose of 2·4 mg/kg on admission, at 
12 h, at 24 h, and thereafter once daily until oral medication 
Figure 3: Treatment eﬀ ect in protocol-speciﬁ ed subgroups
The forest plot shows odds ratios and 95% CIs. The size of the squares is proportional to the size, and therefore weight, of the subgroup. The diamonds show the 
combined diﬀ erences. The eﬃ  cacy of antimalarial pretreatment was classiﬁ ed before study unblinding (webappendix p 12). Hyperparasitaemia means greater than 
10% of red cells parasitised. OR=odds ratio. GCS=Glasgow coma scale. BCS=Blantyre coma scale. BE=base excess. *Site mortality classiﬁ ed as low if the site mortality 
rate was lower than the overall study mortality rate, and high if the site mortality rate was higher than the overall study mortality rate. †Classiﬁ ed according to centre 
policy (ten sites); classiﬁ ed according to individual data (one site). ‡Decompensated or compensated shock. I2 denotes the percentage of total variation across 
subgroups resulting from heterogeneity rather than chance, with the p value of signiﬁ cance.
Pretreatment antimalarial
None
Ineﬀective
Eﬀective
Subtotal (I2=8·9%, p=0·33)
Site mortality*
Low
High
Subtotal (I2=0·0%, p=0·52)
Route of treatment†
Intramuscular
Intravenous
Subtotal (I2=0·0%, p=0·99)
Coma (GCS <11 or BCS <3)
No
Yes
Subtotal (I2=0·0%, p=0·37)
Anaemia (<50 g/L)
No
Yes
Subtotal (I2=0·0%, p=0·52)
Shock‡
No
Yes
Subtotal (I2=19·4%, p=0·38)
Acidosis (BE ≤8 mmol/L)
No
Yes
Subtotal (I2=23·0%, p=0·25)
Respiratory distress‡
No
Yes
Subtotal (I2=19·9%, p=0·26)
Hyperparasitaemia (>10%)
No
Yes
Subtotal (I2=0·0%, p=0·32)
 86/1281 (7%)
 38/387 (10%)
 94/938 (10%)
 65/1183 (5%)
 165/1529 (11%)
 91/933 (10%)
 139/1779 (8%)
 70/1832 (4%)
 160/880 (18%)
 136/1696 (8%)
 77/737 (10%)
 173/2389 (7%)
 57/323 (18%)
 49/1275 (4%)
 149/1009 (15%)
 169/2273 (7%)
 61/439(14%)
 
 140/1766 (8%)
 56/584 (10%)
 125/1270 (10%)
 38/371 (10%)
 124/959 (13%)
 77/1174 (7%)
 220/1539 (14%)
 126/989 (13%)
 171/1724 (10%)
 96/1764 (5%)
 199/945 (21%)
 163/1734 (9%)
 93/692 (13%)
 231/2374 (10%)
 66/339 (19%)
 
 52/1314 (4%)
 189/975 (19%)
 213/2285 (9%)
 84/428 (20%)
 
 167/1779 (9%)
 77/573 (13%)
 
0·66 (0·49–0·88)
1·01 (0·62–1·64)
0·74 (0·55–0·98)
0·74 (0·61–0·89)
0·83 (0·59–1·16)
0·72 (0·58–0·90)
0·75 (0·63–0·90)
0·75 (0·56–1·00)
0·75 (0·59–0·95)
0·75 (0·62–0·90)
0·70 (0·51–0·96)
0·84 (0·66–1·06)
0·78 (0·65–0·95)
0·85 (0·67–1·08)
0·74 (0·53–1·03)
0·81 (0·66–0·98)
0·72 (0·59–0·89)
0·89 (0·59–1·34)
0·75 (0·63–0·91)
0·96 (0·64–1·44)
0·73 (0·58–0·93)
0·79 (0·64–0·97)
0·78 (0·63–0·97)
0·61 (0·42–0·89)
0·74 (0·61–0·89)
0·84 (0·66–1·06)
0·67 (0·47–0·97)
0·78 (0·64–0·96)
1·2510·750·50·4
Artesunate
Events/total (%)
Quinine OR (95% CI)
Events/total (%)
Favours artesunate Favours quinine
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could be taken reliably. The contents of each 60 mg vial 
were dissolved initially in 1 mL 5% sodium bicarbonate 
(provided with the drug) and then diluted with 5% dextrose 
before injection either as a bolus into an indwelling 
intravenous cannula, or administration by deep intra-
muscular injection to the anterior thigh. Quinine di-
hydrochloride (Indus Pharma, Karachi, Pakistan) was 
given in a 20 mg salt per kg loading dose infused over 4 h 
(in 5–10 mL/kg of 5% dextrose), followed by a 10 mg salt 
per kg infusion over 2–8 h three times daily until starting 
oral therapy. For intramuscular treatment the doses were 
the same as for intravenous treatment; quinine was 
diluted in normal saline to a concentration of 60 mg/mL, 
and injected into the anterior thigh. The loading dose was 
given as a split dose into each thigh.
When the patient was able to take tablets, but after 
a minimum of 24 h of parenteral treatment, oral artemether-
lumefantrine (Coartem, Novartis, Basel, Switzerland) in a 
full standard dose (1·5/9 mg/kg twice daily for 3 days with 
milk or fat) was given to complete the treatment.
A 1 mL blood sample was taken for immediate 
haematocrit and biochemical analyses with the EC8+ 
card for a handheld blood analyser (i-STAT, Abbott 
Laboratories, Abbott Park, IL, USA). This device produced 
an immediate printed paper report with time of day, 
which was kept with the case record form. Haemoglobin 
was reported with the i-STAT result or, when not available, 
calculated from the measured haematocrit (n=146).10 
Thick and thin blood smears were prepared for later 
malaria parasite counting at the Bangkok reference 
laboratory. In 109 cases no count was available from the 
reference laboratory, so the parasitaemia reported by the 
study site was used. Children were discharged from 
hospital at the discretion of the physician, and a discharge 
assessment was completed. Children who had not made 
a full neurological recovery by discharge were followed 
up at regular intervals for 12 months or until full recovery. 
Full neurological assessments were completed at every 
visit. Training in neurological assessment was provided 
to all sites by a specialist paediatric neurologist (MO) to 
ensure uniformity.
Trial sites were monitored regularly by Family Health 
International, Nairobi, Kenya. Investigators provided 
reports every 2 weeks to the coordinating centre in 
Bangkok and met every year to review study progress. 
Drug content and quality were checked in ampoules 
taken randomly from the purchase lots (webappendix p 7). 
The data and safety monitoring committee made three 
interim analyses during the trial. Adequacy of random-
isation was assessed by checking by centre that random-
isation was balanced according to baseline variables, and 
by allocation time to assess whether the expected random 
variations were observed.
Study outcomes
The analysis was undertaken according to a prespeciﬁ ed 
analytical plan. The primary outcome measure was in-
hospital mortality compared between treatments on an 
intention-to-treat basis. Secondary outcome measures 
were the incidence of severe neurological complications 
Figure 4: Neurological sequelae at discharge and after 28 days (range 3–8 weeks) in children with severe 
falciparum malaria 
*Some patients had severe impairment in more than one domain.
191 patients with possible neurological deﬁcits at
discharge (110 artesunate, 81 quinine)
21 excluded (11 artesunate, 10 quinine)
4 unspeciﬁed behavioural problems
9 no neurological problem conﬁrmed
4 pre-existing neurological problems
4 mild motor impairment in young
children <18 months
170 patients with neurological sequelae at discharge
(99 artesunate, 71 quinine)
41 lost to follow-up at day 28 (23 artesunate,
18 quinine)
68 sequelae resolved by day 28 (42 artesunate,
26 quinine)
61 patients with neurological sequelae at day 28
(34 artesunate, 27 quinine)
10 mild neurological
sequelae at day 28
(8 artesunate, 2 quinine)
8 moderate neurological
sequelae at day 28
(3 artesunate, 5 quinine)
43 severe neurological sequelae at day 28*
(23 artesunate, 20 quinine; 30 severe motor 
impairment, 14 cortical blindness, 9 severe 
speech or hearing impairment)
Quinine (n/N, %) Artesunate (n/N, %) OR (95% CI) p value
Mortality, ITT analysis 297/2713 (10·9%) 230/2712 (8·5%) 0·75 (0·63–0·90) 0·0022
Mortality, per-protocol analysis 260/2552 (10·2%) 208/2563 (8·1%) 0·78 (0·64–0·94) 0·0099
Death or sequelae at 28 days 316/2695 (11·7%) 253/2689 (9·4%) 0·78 (0·65–0·93) 0·0056
Malaria-attributable mortality* 288/2704 (10·7%) 223/2705 (8·2%) 0·75 (0·63–0·91) 0·0025
Mortality  in strictly deﬁ ned 
severe malaria†
291/2338 (12·4%) 226/2280 (9·9%) 0·77 (0·64–0·93) 0·0055
Case fatality in HIV-positive 
children‡
19/61 (31%) 16/64 (25%) 0·74 (0·33–1·62) 0·45
Development of coma§ 91/1768 (5·1%) 65/1832 (3·5%) 0·69 (0·49–0·95) 0·0231
Deterioration of coma score 208/2713 (7·7%) 166/2712 (6·1%) 0·78 (0·64–0·97) 0·0245
Convulsions developing or 
persisting >6 h after admission
273/2713 (10·1%) 224/2712 (8·3%) 0·80 (0·66–0·97) 0·0199
Hypoglycaemia 75/2713 (2·8%) 48/2712 (1·8%) 0·63 (0·43–0·91) 0·0134
Severe anaemia (<50 g/L) after 
admission§
98/1734 (5·7%) 78/1696 (4·6%) 0·81 (0·59–1·11) 0·18
Blackwater fever§ 18/2597 (0·7%) 30/2591 (1·2%) 1·69 (0·94–3·05) 0·076
ITT=intention to treat. *The likelihood that malaria contributed to or directly caused the death was assessed by an 
independent endpoint review committee blinded to the treatment allocation. †As deﬁ ned in panel 1. ‡HIV status was 
assessed only in Beira, Muheza, and Kiliﬁ  (n=2095). §Development of coma, anaemia, and blackwater fever was 
assessed only in patients without these disorders on admission.
Table 2: Mortality and complications according to treatment group
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(assessed at 28 days, range 3–8 weeks) and a combined 
outcome measure of death and severe persistent 
neurological sequelae. Initially, neurological outcomes 
were assessed only at discharge from hospital, but this 
procedure led to substantial overestimation of neuro-
logical deﬁ cit, especially in young children. The protocol 
was therefore changed in April, 2007, (after 11% of 
patients had been enrolled) so that children who had not 
yet fully recovered at discharge were assessed 28 days 
after enrolment, and active follow-up was instituted. 
Outcome measures were also assessed per protocol, 
excluding patients not fulﬁ lling the entry criteria, those 
with a negative or missing admission blood slide for 
P falciparum, those dying before receiving the study 
drug, and those missing a study drug dose on the ﬁ rst 
day of treatment. Subgroup analyses included 
stratiﬁ cation into two predeﬁ ned groups: those who 
fulﬁ lled the criteria for severe malaria1,2,11 and those who 
did not. In sites at which testing was approved, the HIV 
status of participants was assessed after obtaining a 
separate informed consent, and the outcomes in HIV-1 
infected patients with malaria were compared according 
to treatment allocation.
Two committees were formed to provide independent 
expert assessment and classiﬁ cation of outcomes before 
study unblinding. A neurological outcome committee, 
comprising two experienced paediatricians (both with 
neurological expertise and experience of working 
in Africa) and one clinical malariologist, graded 
neurological sequelae. These sequelae were assessed in 
four domains: motor function, visual function, hearing, 
and speech, and also whether the child had developed 
epilepsy. Sequelae persisting at follow-up were graded as 
mild, moderate, or severe in each domain according to 
the extent of functional impairment (webappendix p 5). 
The overall grade was combined. If there were sequelae 
in more than one functional domain the grade was 
increased. The relation of sequelae to severe malaria was 
assessed taking into account any pre-existing comorbidity. 
A separate endpoint review committee, comprising one 
paediatrician with malaria experience and one clinical 
malariologist, identiﬁ ed cases in which a pathological 
change other than malaria or its acute complications was 
likely to be the main cause of death.
Statistical analysis
Inclusion of more than 5306 children with severe 
malaria was needed to show, with 80% power and 95% 
conﬁ dence, a 25% reduction in mortality from 8% to 
6%. This calculation was based on an estimated severe 
malaria mortality of 16% with about half the enrolled 
patients anticipated to fulﬁ l the criteria for severe 
malaria. Patient data and outcomes were provided to an 
independent data and safety monitoring committee, 
who reviewed the trial yearly.
For binary outcomes, the odds ratios (ORs) between 
treatment groups, stratiﬁ ed by study site, were estimated 
by the Mantel-Haenszel method. Heterogeneity between 
sites was examined with the Breslow-Day test. In Rwanda, 
the two small sites run by the same investigators were 
pooled. Time to event outcomes were compared with the 
log-rank test, and hazard ratios (HRs) were estimated by 
a Cox proportional hazard model, stratiﬁ ed by site. 
Statistical analyses were done with Stata (version 11.1).
This trial is registered, number ISRCTN50258054.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
Figure 1 shows the trial proﬁ le. We recorded no major 
diﬀ erences in baseline characteristics between the two 
treatment groups (table 1). 5425 patients were recruited 
(ﬁ gure 1), of whom 527 (9·7%) died. 230 of 2712 (8·5%) 
patients given artesunate died versus 297 of 2713 (10·9%) 
given quinine (relative risk 0·78, 95% CI 0·66–0·91; OR 
0·75, 0·63–0·90, in favour of artesunate; p=0·0022). This 
represents a relative reduction in mortality of 22·5% 
(95% CI 8·1–36·9%) and corresponds to an overall 
number needed to treat to prevent one death of 41 
(95% CI 25–112). We recorded no heterogeneity between 
study sites (p=0·99). Eight patients (ﬁ ve artesunate, three 
quinine) were taken from hospital against advice and 
could not be followed up further. They were censored in 
the survival analysis at the time of discharge. The survival 
analysis (ﬁ gure 2) for overall mortality during admission 
by antimalarial treatment gives the same result as the 
Mantel-Haenszel analysis (HR stratiﬁ ed by study site 
0·76, 95% CI 0·64–0·91; p=0·0022). Mantel-Haenszel 
analysis of the predeﬁ ned subgroups showed no evidence 
of any diﬀ erences in odds ratios between subgroups 
(ﬁ gure 3), and these results were conﬁ rmed by Cox 
regression (data not shown).
The per-protocol analysis excluded patients who died 
rapidly before receiving antimalarial treatment (six 
artesunate, 22 quinine; p=0·0023), patients with 
incomplete initial antimalarial treatment with the study 
drug, and those with negative or missing blood slides for 
Quinine 
(median, IQR)
N Artesunate 
(median, IQR)
N HR (95% CI) p value
Time to discharge (days) 3·0 (2·0–5·0) 2412 3·0 (2·0–5·0) 2478 1·04 (0·99–1·10) 0·059
Time to eat (h) 12 (2–24) 2269 9 (0–24) 2358 0·99 (0·93–1·06) 0·74
Time to sit unsupported (h) 22 (6–44) 2312 18 (6–42) 2373 1·02 (0·95–1·08) 0·60
Time to localise pain (h)* 12 (6–24) 726 12 (6–24) 698 0·87 (0·78–0·98) 0·0093
Time to speak (h)* 18 (11–36) 695 20 (8–42) 664 0·88 (0·79–0·99) 0·016
*Time to localise pain and time to speak was assessed only for surviving patients with coma on admission 
(Blantyre coma scale <3 or Glasgow coma scale <11).
Table 3: Recovery times in surviving patients according to treatment group
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P falciparum (ﬁ gure 1), but these omissions did not 
substantially aﬀ ect the result (table 2). The endpoint 
review committee identiﬁ ed 16 children (seven artesunate, 
nine quinine) in whom death was unlikely to be related 
to severe malaria. Omission of these cases from the 
analysis also had no eﬀ ect on the magnitude of the 
survival beneﬁ t with artesunate (table 2 and 
webappendix p 3). In 4618 children fulﬁ lling strict criteria 
for severe malaria (panel 1), mortality was 9·9% 
(226/2280) with artesunate and 12·4% (291/2338) with 
quinine (OR 0·77, 95% CI 0·64–0·93; p=0·0055). Eight 
fatal cases (ﬁ ve quinine, three artesunate) did not have 
an accurate time of death recorded. In the remainder, 
345 of 519 deaths occurred within the ﬁ rst 24 h after 
admission, of which 158 of 2709 (5·8%) were assigned to 
artesunate treatment and 187 of 2708 (6·9%) to quinine 
treatment (OR 0·84, 95% CI 0·67–1·04, p=0·109). Of the 
174 of 519 deaths that occurred more than 24 h after 
admission, 69 of 2551 (2·7%) patients were treated with 
artesunate and 105 of 2521 (4·2%) with quinine (OR 
0·63, 0·47–0·87, p=0·004). HIV serology was assessed 
routinely in Beira, Muheza, and Kiliﬁ . Of 2095 patients 
tested, 125 (6%) were positive (64 artesunate, 61 quinine). 
Mortality in these patients was high (table 2).
497 children (224 artesunate, 273 quinine) had 
convulsions that either developed after admission, 
irrespective of duration, or were present on admission and 
persisted for more than 6 h, and 156 patients (65 artesunate, 
91 quinine) developed coma or had a deterioration of their 
coma score after starting anti malarial treatment (table 2). 
The development of coma, deterioration in coma score, 
and convulsions all occurred more frequently in patients 
who received quinine than in those who received artesunate 
(table 2). In the 4898 survivors, 170 (99 artesunate, 
71 quinine) had not yet made full neurological recoveries at 
discharge (ﬁ gure 4). Of these patients, 129 (76 artesunate, 
53 quinine) were followed up between 3 and 8 weeks after 
enrolment. At this ﬁ rst follow-up assessment 68 (53%) had 
recovered fully, 18 (14%; 11 artesunate, seven quinine) were 
mildly or moderately impaired, and 43 (33%; 20 quinine, 
23 artesunate) had severe neurological deﬁ cits. The overall 
incidence of any persistent neurological sequelae in 
assessed survivors at 28 days after cerebral malaria was 
3·2% (24/706 artesunate, 23/737 quinine) and of severe 
neurological sequelae was 2·3% (17/706 artesunate, 
17/737 quinine). We recorded no diﬀ erence between the 
treatment groups. Of the 14 patients with any neurological 
sequelae who did not have cerebral malaria initially 
(ten artesunate, four quinine), seven had multiple 
convulsions (three quinine, four artesunate) and all had 
severe prostration on admission.
We detected no severe adverse eﬀ ects that could be 
attributed directly to drug toxicity. Although one patient 
treated with artesunate developed a mild urticarial rash, 
no severe type 1 hypersensitivity reactions were recorded. 
Another patient treated with artesunate developed 
peripheral gangrene of toes and ﬁ ngers, which was 
attributed to the disease and not the drug. One patient 
given quinine developed severe stridor after 
administration of ampicillin, and died. This death was 
attributed to ampicillin rather than quinine. 
Hypoglycaemia after starting antimalarial treatment was 
signiﬁ cantly less frequent in patients who received 
artesunate than in those who received quinine (table 2). 
Blackwater fever was rare in both groups (table 2).
Blood transfusions were given to 1487/2712 (55%) 
patients assigned to artesunate and 1495/2713 (55%) 
assigned to quinine. A ﬂ uid bolus at the start of treatment 
was given to 589/2712 (22%) patients assigned to 
artesunate and 596/2713 (22%) assigned to quinine. 
3259 (60%) children received antibiotics (1606 artesunate, 
1653 quinine; p=0·20).
In cerebral malaria survivors, the time from 
randomisation until the child was able to localise a 
Figure 5: Meta-analysis of all randomised controlled trials that have compared mortality of severe malaria in patients treated with parenteral artesunate 
versus parenteral quinine12–16
The solid vertical line represents equality of the two groups; the dashed line is the overall treatment diﬀ erence. The horizontal lines and the width of the diamonds 
show the CIs for the odds ratios. The size of the squares is proportional to the size, and therefore weight, of the trial. OR=odds ratio. *99% CIs for totals. 
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painful stimulus or was able to speak was slightly longer 
overall in patients treated with artesunate than in those 
given quinine when compared by survival analysis 
(table 3). The times to eat or to sit unsupported did not 
diﬀ er between treatment groups (table 3).
The content of artesunate in all ampoules tested was 
within the pharmaceutical content limits of 10% of the 
stated active ingredient. All tested vials of quinine 
contained between 105% and 112% of the stated content 
(webappendix p 7).
In a meta-analysis of all severe malaria trials that have 
compared survival after parenteral artesunate with that 
after parenteral quinine, the overall OR was 0·69 
(0·57–0·84; p<0·00001) in favour of artesunate (ﬁ gure 5). 
We noted no signiﬁ cant heterogeneity between the 
results generated in Africa and Asia (ﬁ gure 5). 
Discussion
This large multicentre trial shows that artesunate 
substantially reduces the overall mortality of African 
children diagnosed with severe malaria. We recorded 
little heterogeneity between treatment centres in the 
beneﬁ t associated with artesunate, suggesting that the 
ﬁ ndings are robust. Before this trial, concerns had been 
raised that artesunate might not be better than quinine in 
African children, whereas it clearly was in Asian patients. 
The concerns arose because of perceived diﬀ erences in 
pathology and the prevalence of more quinine-susceptible 
malaria parasites, and because in the earlier SEAQUAMAT 
trial undertaken in Asia,7 the survival curves did not 
separate clearly until 48 h after starting treatment, 
whereas most deaths in African children occurred before 
this time. Fortunately these concerns were not 
substantiated. More than 7000 severely ill patients have 
now been included in randomised comparisons of 
parenteral artesunate and quinine (ﬁ gure 5). Compared 
with parenteral quinine, artesunate reduced the mortality 
of severe malaria in African children by 22·5%, and in 
Asian patients by 38·6%.7 These studies together 
comprise nearly 80% of all patients ever enrolled in 
randomised controlled trials of patients admitted with 
severe malaria, and they provide deﬁ nitive evidence that 
artesunate is the most eﬀ ective available treatment for 
severe malaria, and that it is safe (panel 2).
This multicentre trial was open label because the 
substantial diﬀ erences in the parenteral formulations of 
the two drugs prevented adequate concealment. Although 
individual trial site investigators knew the individual 
treatment allocations, all the other clinical and laboratory 
investigators were masked to the parenteral treatments 
given. The similarity of results across the diﬀ erent trial 
sites suggests that signiﬁ cant bias was unlikely. The great 
strength of this trial is its unprecedented size, its 
consistency both internally and with previous studies, 
and therefore the conﬁ dence that health-care workers 
throughout the tropical world can have in its result.
Artesunate prevented death from severe malaria, but 
not at the expense of an increase in neurological sequelae. 
Indeed, the overall incidence of conﬁ rmed persistent 
severe sequelae after severe malaria was low.17 Initially 
the assessment of neurological deﬁ cit was made at 
discharge from hospital, but many children, especially in 
the younger age group, had not made a full neurological 
recovery at discharge. Subsequently, assessments were 
made 4 weeks later, by which time about half the apparent 
deﬁ cits had resolved fully.
This life-saving beneﬁ t of artesunate compared with 
quinine in severe malaria has to derive from its greater 
intrinsic parasiticidal activity. The principal pharma-
codynamic advantage of artesunate is that it has a much 
broader stage-speciﬁ city of action than does quinine.18 
The artemisinins kill circulating ring-stage parasites 
before they can mature,19,20 which reduces sequestration 
of infected erythrocytes in the venules and capillaries of 
vital organs and thereby prevents potentially lethal 
microvascular obstruction.21–23 The large and consistent 
reduction in mortality associated with artesunate, and 
the consistent ﬁ nding that mortality reduction is greatest 
in hyperparasitaemia,7 lends support to the central 
quantitative role of parasitised erythrocyte sequestration 
in the pathology of malaria. 
The beneﬁ ts of parenteral artesunate compared with 
quinine were greater than the beneﬁ ts of intramuscular 
artemether reported in previous trials.6,7 In a double-blind 
trial24 comparing artesunate and artemether in 
370 Vietnamese adults with severe falciparum malaria, 
13 patients died in the artesunate group (7%) and 24 in 
the artemether group (13%). Taken together, these 
diﬀ erent study results suggest that the live-saving beneﬁ t 
compared with quinine provided by artesunate is roughly 
twice that provided by artemether. Artesunate and 
artemether have similar pharmacodynamic properties in 
vitro, so the most likely explanation for their diﬀ erent 
Panel 2: Research in context
Systematic review
We searched Medline (from January, 1966, to September, 
2010) and Embase (from January, 1980, to September, 2010) 
for randomised controlled trials. Search terms used were: 
“malaria”, “cerebral malaria”, “severe malaria”, “complicated 
malaria”, “malaria falciparum”, “quinine”, and “cinchona 
alkaloids” (MeSH/EMTREE terms); and “artemisinin” and 
“artesunate”. We searched for randomised controlled trials 
that compared parenteral artesunate with quinine for 
treatment of severe malaria. We identiﬁ ed six randomised 
controlled trials,7,12–16 which we have included in the meta-
analysis presented in ﬁ gure 5.
Interpretation
Together these trials provide substantial evidence of the life-
saving beneﬁ t of artesunate compared with quinine in the 
treatment of severe falciparum malaria in all age groups 
worldwide.
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eﬃ  cacies in vivo is the substantial diﬀ erence in their 
pharmacokinetic properties. Parenteral artemether is an 
oil-based formulation given only by intramuscular 
injection. Absorption is slow and erratic, whereas the 
water-soluble hemisuccinate artesunate is absorbed 
rapidly and reliably after intramuscular injection and can 
be given intravenously.25–30 Thus the pharmacodynamic 
advantage of artemether over quinine might have been 
oﬀ set by its poor absorption kinetics. In summary, in the 
treatment of severe falciparum malaria, it seems that 
artesunate is better than artemether, which in turn is 
better than quinine.
The beneﬁ ts of artesunate (and artemether) compared 
with quinine were greater in patients from southeast 
Asia than in African children,6,7 although the studies were 
not large enough to show this diﬀ erence reliably. There 
are several possible explanations for this ﬁ nding. African 
children usually have some background immunity that 
assists the therapeutic response, and in particular 
accelerates circulating parasite clearance.31 This eﬀ ect 
hastens recovery and could reduce the therapeutic 
advantage of artesunate. The greater quinine susceptibility 
of P falciparum in Africa is often proposed as contributing 
to improved therapeutic responses, but the diﬀ erences 
are not large, and are unlikely to have a major eﬀ ect in 
vivo. Incorrect diagnosis is likely to be a major 
contributory factor; severe malaria is overdiagnosed in 
African children, and sepsis is underdiagnosed.32 Febrile 
sick children with positive malaria blood smears are 
usually diagnosed initially as having severe malaria, but 
the speciﬁ city of a positive blood smear is poor in settings 
in which a high proportion of all children are parasitaemic. 
Septicaemia and pneumonia are especially diﬃ  cult to 
diﬀ erentiate clinically from severe malaria. Sepsis and 
severe malaria also commonly coexist in African 
children.32 Prompt and appropriate treatment of sepsis 
should further reduce the mortality of severely ill children 
with malaria parasitaemia.
Parenteral artesunate is simple to administer, is safe, 
and reduces mortality substantially compared with 
quinine. No serious adverse eﬀ ects were identiﬁ ed in 
this large study or in previous large studies.7,24,33 By 
contrast, intramuscular quinine is locally toxic4 (because 
of its acidity), and intravenous quinine needs a carefully 
rate-controlled infusion and continuous or three times 
daily administration to avoid dangerous hypotension.9 
Importantly, quinine is associated with potentially serious 
hypoglycaemia.1,2,5 In this trial, 22 children died before 
receiving quinine compared with only six who died 
before receiving artesunate. This ﬁ nding is probably 
indicative of the diﬃ  culties in administering parenteral 
quinine promptly and safely. Any delay in treating severe 
infection will increase mortality.33 The ease and safety of 
parenteral artesunate are important practical advantages. 
Artesunate is more expensive to buy, but quinine is more 
expensive to administer. A major factor restricting the 
deployment of artesunate has been unavailability of a 
product satisfying international good manufacturing 
standards. The most widely used product, assessed in 
this study, does not yet have this certiﬁ cation, which has 
prevented deployment in some countries.34–39 This barrier 
must be overcome speedily so that parenteral artesunate 
can be deployed in malaria-endemic areas to save lives.
Artesunate should now become the treatment of choice 
for severe malaria for children and adults worldwide. 
Malaria causes an estimated 800 000 deaths every year in 
African children.40 Severe malaria is often the most 
common admission diagnosis in febrile children, so a 
change in treatment policy from quinine to artesunate 
has the potential to save thousands of children’s lives 
every year. If 4 million African children with severe 
malaria every year were to receive prompt treatment with 
parenteral artesunate instead of quinine, and the beneﬁ ts 
were similar to those recorded in this trial, then 
approximately 100 000 lives might be saved per year. 
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